Team:Brown
From 2009.igem.org
Line 8: | Line 8: | ||
== Welcome to the Brown iGEM wiki! == | == Welcome to the Brown iGEM wiki! == | ||
- | <font><font color="white">Brown iGEM is a team of nine undergraduate students from diverse backgrounds in science and engineering. We are mentored by Brown graduate students, postdocs, and faculty from across the university. With support from Brown Undergraduate Teaching and Research Awards and Brown Multidisciplinary Labs, we have been conducting unique research and experiments over the past 4 months in preparation for iGEM jamboree at MIT in November 2009. The 2009 Brown iGEM team aims to treat allergic rhinitis by taking an innovative synthetic biological approach | + | <font><font color="white">Brown iGEM is a team of nine undergraduate students from diverse backgrounds in science and engineering. We are mentored by Brown graduate students, postdocs, and faculty from across the university. With support from Brown Undergraduate Teaching and Research Awards and Brown Multidisciplinary Labs, we have been conducting unique research and experiments over the past 4 months in preparation for iGEM jamboree at MIT in November 2009. The 2009 Brown iGEM team aims to treat allergic rhinitis by taking an innovative synthetic biological approach to create self-regulating drug factory in the nose. |
==== | ==== | ||
- | |||
+ | <div id="team_box"> | ||
+ | <h3>The Problem</h3> | ||
+ | <p>Every year, over fifty million people in the US suffer from allergic rhinitis, the most common type of allergy. Allergens, such as pollen, dust, and dander result in nasal congestion, itching, burning, sneezing, and overall discomfort. Current treatments include over-the-counter antihistamines, however, side effects of these drugs include drowsiness, restlessness, and poor concentration. For patients suffering from chronic allergies and inflammation, there is a great need for an alternative strategy for combating allergic symptoms without causing significant side effects. </p></div> | ||
- | The 2009 Brown University iGEM team worked to treat allergic rhinitis | + | <div id="objective_box"> |
- | + | <h3>The Objective</h3> | |
- | The engineered strain of S. epidermidis will function as a self-regulating drug factory in the nose, providing relief, without any negative side effects. | + | <p>The 2009 Brown University iGEM team worked to treat allergic rhinitis by engineering Staphylococcus epidermidis, a microbe endogenous to the human nasal flora, to secrete a recombinant histamine-binding protein in response to the elevated histamine concentrations of an allergic response. The engineered strain of S. epidermidis will function as a self-regulating drug factory in the nose, providing relief, without any negative side effects. |
Revision as of 17:50, 15 October 2009
Contents |
Welcome to the Brown iGEM wiki!
Brown iGEM is a team of nine undergraduate students from diverse backgrounds in science and engineering. We are mentored by Brown graduate students, postdocs, and faculty from across the university. With support from Brown Undergraduate Teaching and Research Awards and Brown Multidisciplinary Labs, we have been conducting unique research and experiments over the past 4 months in preparation for iGEM jamboree at MIT in November 2009. The 2009 Brown iGEM team aims to treat allergic rhinitis by taking an innovative synthetic biological approach to create self-regulating drug factory in the nose.
==
The Problem
Every year, over fifty million people in the US suffer from allergic rhinitis, the most common type of allergy. Allergens, such as pollen, dust, and dander result in nasal congestion, itching, burning, sneezing, and overall discomfort. Current treatments include over-the-counter antihistamines, however, side effects of these drugs include drowsiness, restlessness, and poor concentration. For patients suffering from chronic allergies and inflammation, there is a great need for an alternative strategy for combating allergic symptoms without causing significant side effects.
The Objective
The 2009 Brown University iGEM team worked to treat allergic rhinitis by engineering Staphylococcus epidermidis, a microbe endogenous to the human nasal flora, to secrete a recombinant histamine-binding protein in response to the elevated histamine concentrations of an allergic response. The engineered strain of S. epidermidis will function as a self-regulating drug factory in the nose, providing relief, without any negative side effects.